Xiamen Weiyang

Xiamen Weiyang Biotechnology is a Chinese medical technology company specializing in the research, development, and manufacturing of in vitro diagnostic (IVD) products. The company focuses on Point-of-Care Testing (POCT) solutions, offering a range of rapid diagnostic kits for infectious diseases, cardiac markers, and inflammatory indicators. Their product portfolio includes tests for COVID-19, Influenza, Troponin I, and C-reactive protein, utilizing technologies such as colloidal gold and fluorescence immunochromatography. Xiamen Weiyang operates a GMP-certified manufacturing facility in the Xiamen Haicang Bio-pharmaceutical Port and serves both domestic and international markets. The company's diagnostic platforms are designed for high sensitivity and ease of use in various clinical settings, including hospitals and emergency rooms. By providing efficient and accurate diagnostic tools, Xiamen Weiyang aims to improve clinical decision-making and patient outcomes globally.